Please login to the form below

Not currently logged in
Email:
Password:

Intercept

This page shows the latest Intercept news and features for those working in and with pharma, biotech and healthcare.

Gilead drives NASH development with insitro collaboration

Gilead drives NASH development with insitro collaboration

The chances of that being a Gilead candidate is overshadowed by Intercept’s recent FDA filing of its own NASH candidate Ocaliva, although that drug is making investors nervous with its

Latest news

  • Intercept builds its case for Ocaliva in NASH, but safety still an issue Intercept builds its case for Ocaliva in NASH, but safety still an issue

    Mixed efficacy and safety results hits NASH frontrunner. Intercept has presented further data backing the efficacy of Ocaliva in non-alcoholic steatohepatitis (NASH), but side effects are still making investors nervous. ... Intercept also reported new

  • Genfit launches $135m IPO to back NASH plans Genfit launches $135m IPO to back NASH plans

    Trailing rivals Intercept in race to market. Genfit has priced its initial public offering (IPO) in the US as it looks to raise $135m to help advance its drug for ... There are no approved therapies at the moment, but several candidates are coming

  • Liver specialist Genfit files $120m IPO on Nasdaq Liver specialist Genfit files $120m IPO on Nasdaq

    Shortly afterwards, Intercept Pharma reported somewhat mixed phase 3 data for its NASH drug obeticholic acid, although analysts suggested the data could still be enough to support an FDA approval.

  • Intercept NASH drug closes in on FDA approval Intercept NASH drug closes in on FDA approval

    Although the drug failed to meet secondary endpoint. Intercept looks like it could become the first biopharma company to get a drug for non-alcoholic steatohepatitis (NASH) approved for marketing, although ... Intercept’s trial enrolled mainly patients

  • Gilead awaits CEO and readouts to revive fortunes Gilead awaits CEO and readouts to revive fortunes

    Two parallel trials, STELLAR 3 and STELLAR 4 of selonsertib will be crucial to its success, and will be compared with data from Intercept’s Ocaliva, its biggest rival to become

More from news
Approximately 8 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    In Europe Cerus expects to apply for a CE Mark for the Intercept RBC System in the second half of 2016. ... collaboration, licence. 200. Cerus/ BARDA. Intercept, pathogen reduction technology for blood transfusions including Zika virus.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics